Clinical Trials Browser

OTHER × Interventional × padeliporfin × Clear all

Transitional Cell Cancer of Renal Pelvis and Ureter

NCT03315754 2024-12-20

Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.

Phase 2 Active not recruiting

50 enrolled 8 charts

Genitourinary

Localized Prostate Cancer

NCT04225299 2020-11-13

Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer

Phase 3 Withdrawn

Genitourinary

Carcinoma, Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT01310894 2019-07-11

PCM301

Phase 3 Completed

413 enrolled

Genitourinary

Carcinoma, Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT00707356 2016-04-19

Study of WST11 in Patients With Localized Prostate Cancer

Phase 2 Completed

42 enrolled

Genitourinary

Genital Diseases, Carcinoma, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT00975039 2016-04-18

Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma

Phase 2 Terminated

8 enrolled

Gastrointestinal

Carcinoma, Cholangiocarcinoma

NCT00974662 2015-04-28

Study Using WST11 in Patients With Obstructing Endobronchial Non-Small Cell Lung Cancer

Phase 2 Terminated

3 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00975429 2015-04-28

Study Using WST11 in Patients With Localized Prostate Cancer

Phase 2 Completed

86 enrolled

Genitourinary

Carcinoma, Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

Clinical Trials

UCM301

Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.

Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer

PCM301

Study of WST11 in Patients With Localized Prostate Cancer

Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma

Study Using WST11 in Patients With Obstructing Endobronchial Non-Small Cell Lung Cancer

Study Using WST11 in Patients With Localized Prostate Cancer